Enterprise Value

1.378B

Cash

278.4M

Avg Qtr Burn

-26.94M

Short % of Float

13.93%

Insider Ownership

0.31%

Institutional Own.

-

Qtr Updated

03/31/23


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date

Phase 2

Data readout

Barzolvolimab (CDX-0159) Details
Eosinophilic Esophagitis, Eosinophilic Gastritis

Phase 2

Initiation

Barzolvolimab (CDX-0159) (KIT receptor) Details
Skin disease/disorder, Prurigo nodularis

Phase 1b

Data readout

CDX-585 Details
Solid tumor/s, Cancer

Phase 1

Update

CDX-1140 (CD40 agonist) Details
Solid tumor/s, Cancer, Diffuse large B cell lymphoma

Failed

Discontinued

Failed

Discontinued